Novavax (NVAX) Stock Forecast & Price Target

Compare

10,122 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVAX Analyst Ratings

Hold

4 Buy

1 Hold

3 Sell

Based on 8 analysts giving stock ratings to

Novavax

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVAX Stock 12 Month Forecast

Average Price Target

$11.25

▲(15.38% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $11.25 with a high forecast of $19.00 and a low forecast of $6.00. The average price target represents a 15.38% change from the last price of $9.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","8.75":"$8.75","12.5":"$12.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.75,12.5,16.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.72,7.664615384615384,8.60923076923077,9.553846153846154,10.49846153846154,11.443076923076923,12.387692307692308,13.332307692307694,14.276923076923078,15.221538461538461,16.166153846153847,17.110769230769233,18.055384615384618,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.72,7.068461538461539,7.4169230769230765,7.765384615384615,8.113846153846154,8.462307692307693,8.810769230769232,9.159230769230769,9.507692307692308,9.856153846153846,10.204615384615384,10.553076923076922,10.901538461538461,{"y":11.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.72,6.664615384615384,6.609230769230769,6.553846153846154,6.498461538461538,6.443076923076923,6.387692307692308,6.332307692307692,6.276923076923077,6.2215384615384615,6.166153846153846,6.110769230769231,6.055384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.04,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.33,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.69,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$11.25

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alec Stranahan

Bank of America Securities

Sell

-28.21%

Downside

Reiterated

01/22/26

Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook

Thomas Shrader

BTIG

$19

Buy

94.87%

Upside

Reiterated

01/20/26

Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy

Sean Lee CFA

H.C. Wainwright

$11

Buy

12.82%

Upside

Reiterated

01/20/26

Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating

Pete Stavropoulos

Cantor Fitzgerald

$18

Buy

84.62%

Upside

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Geoff Meacham

Citi

Sell

-38.46%

Downside

Reiterated

01/05/26

Citi Remains a Sell on Novavax (NVAX)

Anupam Rama

J.P. Morgan

$7→$6

Sell

-38.46%

Downside

Reiterated

11/18/25

Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan

Mayank Mamtani

B. Riley Securities

$16

Buy

64.10%

Upside

Reiterated

11/11/25

Novavax price target lowered to $16 from $18 at B. RileyNovavax price target lowered to $16 from $18 at B. Riley

Chris LoBianco

TD Cowen

Not Ranked

TD Cowen

$8→$7

Hold

-28.21%

Downside

Reiterated

11/04/25

Novavax (NVAX) Gets a Hold from TD Cowen

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alec Stranahan

Bank of America Securities

Sell

-28.21%

Downside

Reiterated

01/22/26

Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook

Thomas Shrader

BTIG

$19

Buy

94.87%

Upside

Reiterated

01/20/26

Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy

Sean Lee CFA

H.C. Wainwright

$11

Buy

12.82%

Upside

Reiterated

01/20/26

Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating

Pete Stavropoulos

Cantor Fitzgerald

$18

Buy

84.62%

Upside

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Geoff Meacham

Citi

Sell

-38.46%

Downside

Reiterated

01/05/26

Citi Remains a Sell on Novavax (NVAX)

Anupam Rama

J.P. Morgan

$7→$6

Sell

-38.46%

Downside

Reiterated

11/18/25

Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan

Mayank Mamtani

B. Riley Securities

$16

Buy

64.10%

Upside

Reiterated

11/11/25

Novavax price target lowered to $16 from $18 at B. RileyNovavax price target lowered to $16 from $18 at B. Riley

Chris LoBianco

TD Cowen

Not Ranked

TD Cowen

$8→$7

Hold

-28.21%

Downside

Reiterated

11/04/25

Novavax (NVAX) Gets a Hold from TD Cowen

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novavax

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+18.62%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +18.62% per trade.

1 Year

Alec StranahanBank of America Securities

Success Rate

9/16 ratings generated profit

Average Return

+11.84%

reiterated a sell rating 2 days ago

Copying Alec Stranahan's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +11.84% per trade.

2 Years

xxx

Success Rate

9/16 ratings generated profit

Average Return

+6.30%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +6.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVAX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVAX has received 5 Buy Ratings, 42 Hold Ratings, and 9 Sell Ratings. NVAX average Analyst price target in the past 3 months is 11.25.

Each month's total comprises the sum of three months' worth of ratings.

NVAX Financial Forecast

NVAX Earnings Forecast

Next quarter’s earnings estimate for NVAX is -$0.49 with a range of -$1.37 to -$0.11. The previous quarter’s EPS was -$1.25. NVAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.

NVAX Sales Forecast

Next quarter’s sales forecast for NVAX is $90.25M with a range of $71.00M to $167.00M. The previous quarter’s sales results were $70.44M. NVAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.92% of the time in the same period. In the last calendar year NVAX has Performed in-line its overall industry.

NVAX Stock Forecast FAQ

What is NVAX’s average 12-month price target, according to analysts?

Based on analyst ratings, Novavax’s 12-month average price target is 11.25.

What is NVAX’s upside potential, based on the analysts’ average price target?

Novavax has 15.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVAX a Buy, Sell or Hold?

Novavax has a consensus rating of Hold which is based on 4 buy ratings, 1 hold ratings and 3 sell ratings.

What is Novavax’s price target?

The average price target for Novavax is 11.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $6.00. The average price target represents 15.38% Increase from the current price of $9.75.

What do analysts say about Novavax?

Novavax’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of NVAX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Novavax (NVAX) Stock Forecast & Price Target

NVAX Analyst Ratings

NVAX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novavax

NVAX Analyst Recommendation Trends

NVAX Financial Forecast

NVAX Earnings Forecast

NVAX Sales Forecast

NVAX Stock Forecast FAQ

Detailed List of Analyst Forecasts